Monoclonal Antibodies Look to a Bright Future
Using mAbs as therapeutics could cut preclinical development time by as much as two-thirds and cost by even greater levels.

Genomics Sector Has Fired More Than 1,500 Staff Since January 2001
The following is a general compilation of the number of employees at genomic tool and tech firms who have lost their jobs as the industry, bookended by slowdowns at biotech and pharma customers, struggles to stay afloat.

Biotech Not Cratering, Just Deflating
To see where the biotech sector is headed tomorrow, it might be helpful for investors to look back, and more importantly, forget about, the recent past.

Cuba seeks new drug markets
Inside modern towers that are a pride of Fidel Castro, scientists peer through huge microscopes at tiny proteins they hope to tailor to treat such major killers as AIDS, heart disease and cancer.

Time to Let the Air Out
If you think biotech stocks are headed for a breakout anytime soon, allow us to burst your bubble

FDA rules need tweaking
The biotech industry is suffering a mini-crisis of confidence that mirrors the larger shocks that have sent Wall Street reeling.

deCODED?
A new map of the human genome should help both doctors and biologists

Will R&D Make Merck Hot Again?
The drug giant gets out of the prescription business and bets it all on science.

Cracking the cancer code
Whether a tumor invades the lung or breast is beside the point. Its genetic activity will dictate how to attack it

Report raps drug firms’ ‘post-approval’ studies
Drug manufacturers spent $1.5 billion in 2000 to test medicines already approved by the Food and Drug Administration primarily so they could make new marketing claims to sell their products, industry specialists said this week. Critics say the trend inflates health care costs while undercutting the integrity of research.